Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 12Carcinoma, Non-Small-Cell Lung 8Uterine Cervical Neoplasms 6Carcinoma, Renal Cell 5Rectal Neoplasms 4Pancreatic Neoplasms 4Colonic Neoplasms 4Sarcoma 3Neoplasms 3Lymphoma 3Lung Neoplasms 3Hodgkin Disease 3Breast Neoplasms, Male 3Thyroid Neoplasms 2Thyroid Cancer, Papillary 2Oropharyngeal Neoplasms 2Liver Neoplasms 2Kidney Neoplasms 2Colorectal Neoplasms 2Carcinoma, Hepatocellular 2Adenocarcinoma, Follicular 2von Hippel-Lindau Disease 1Vaginal Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Tongue Neoplasms 1Stomach Neoplasms 1Stage III Lung Non-Small Cell Cancer AJCC v7 1Squamous Cell Carcinoma of Head and Neck 1Spinal Cord Neoplasms 1

Interventions

tanespimycin 1gallium Ga 68 dotatate 1Sunitinib 1PT2385 1Oxygen-15 1Fluorodeoxyglucose F18 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × von Hippel-Lindau Disease × Fluorodeoxyglucose F18 × Clear all
NCT00088374 2012-07-27

17AAG to Treat Kidney Tumors in Von Hippel-Lindau Disease

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
9 enrolled 8 charts
Genitourinary

Carcinoma, Renal Cell, von Hippel-Lindau Disease, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡